MedWatch

Prominent investors criticize Lundbeck's share structure split

Pharmaceutical firm Lundbeck’s recently proposed split share structure has not been well received by some big investors.

Photo: Lundbeck / PR

Last week, Lundbeck announced a new share structure dividing shares into two categories, which would allow the company to hunt for external financing without the Lundbeck Foundation, which is the majority shareholder, having to relinquish any power.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs